# Tdv PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tdv

> The next catalyst for tdv, sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), is its topline data readout, Apr to Jul 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | tdv |
| Codes | TAK-003 |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | [Healthy Volunteers](https://sec-api.dev/indications/healthy-volunteers), [Dengue Fever](https://sec-api.dev/indications/dengue-fever) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### May 5, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Healthy Volunteers.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06060067 (A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-05 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-05-29." https://clinicaltrials.gov/study/NCT06060067

### July 9, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2/3. Indication: Dengue Fever.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06741683 (A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-07-09 (ACTUAL); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06741683

### May 29, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Healthy Volunteers.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06060067 (A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-05 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-05-29." https://clinicaltrials.gov/study/NCT06060067?tab=results

### Apr to Jul 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Dengue Fever.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06579755 (A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-14 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06579755

### April 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Dengue Fever.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06579755 (A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-14 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06579755

### Mar to Jun 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Dengue Fever.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06665035 (A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-03 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06665035

### March 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Dengue Fever.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06665035 (A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-03 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06665035

## Same indication

- [Tetravalent dengue vaccine (tdv)](https://sec-api.dev/pdufa/tetravalent-dengue-vaccine-tdv) (TAK)

Calendar months: [April 2027](https://sec-api.dev/fda-calendar/2027-04)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tdv.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Tdv PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tdv

```bibtex
@misc{secapidev_pdufa_tdv_20261116,
  title        = {Tdv PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tdv}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tdv_20261116","title":"Tdv PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tdv","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
